Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
A comprehensive analysis of Italian web pages mentioning squalene-based influenza vaccine adjuvants reveals a high prevalence of misinformation. Panatto D et al. Hum Vaccin Immunother. (2018)
Genotoxicity assessment of vaccine adjuvant squalene. Yüzbaşıoğlu D et al. Food Chem Toxicol. (2013)
Effects of squalene/squalane on dopamine levels, antioxidant enzyme activity, and fatty acid composition in the striatum of Parkinson's disease mouse model. Kabuto H et al. J Oleo Sci. (2013)
A comprehensive analysis of Italian web pages mentioning squalene-based influenza vaccine adjuvants reveals a high prevalence of misinformation.
Panatto D, Amicizia D, Arata L, Lai PL, Gasparini R.
Hum Vaccin Immunother. 2018 Apr 3;14(4):969-977. doi: 10.1080/21645515.2017.1407483. Epub 2018 Jan 3.
Similar articles
Preclinical Pharmacology and Pharmacokinetics of Inhaled Hexadecyl-Treprostinil (C16TR), a Pulmonary Vasodilator Prodrug.
Corboz MR, Li Z, Malinin V, Plaunt AJ, Konicek DM, Leifer FG, Chen KJ, Laurent CE, Yin H, Biernat MC, Salvail D, Zhuang J, Xu F, Curran A, Perkins WR, Chapman RW.
J Pharmacol Exp Ther. 2017 Dec;363(3):348-357. doi: 10.1124/jpet.117.242099. Epub 2017 Sep 13.
Evaluation of a primary course of H9N2 vaccine with or without AS03 adjuvant in adults: A phase I/II randomized trial.
Madan A, Collins H, Sheldon E, Frenette L, Chu L, Friel D, Drame M, Vaughn DW, Innis BL, Schuind A.
Vaccine. 2017 Aug 16;35(35 Pt B):4621-4628. doi: 10.1016/j.vaccine.2017.07.013. Epub 2017 Jul 15.
Adjuvanted (AS03) A/H1N1 2009 Pandemic Influenza Vaccines and Solid Organ Transplant Rejection: Systematic Signal Evaluation and Lessons Learnt.
Dos Santos G, Seifert HA, Bauchau V, Shinde V, Barbeau DM, Cohet C.
Drug Saf. 2017 Aug;40(8):693-702. doi: 10.1007/s40264-017-0532-3.
Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine and an MF59-adjuvanted influenza vaccine after concomitant vaccination in ⩾60-year-old adults.
Song JY, Cheong HJ, Hyun HJ, Seo YB, Lee J, Wie SH, Choi MJ, Choi WS, Noh JY, Yun JW, Yun JG, Kim WJ.
Vaccine. 2017 Jan 5;35(2):313-320. doi: 10.1016/j.vaccine.2016.11.047. Epub 2016 Dec 3.
Alp Rose stem cells, olive oil squalene and a natural alkyl polyglucoside emulsifier: Are they appropriate ingredients of skin moisturizers - in vivo efficacy on normal and sodium lauryl sulfate - irritated skin?.
Filipović M, Gledović A, Lukić M, Tasić-Kostov M, Isailović T, Pantelić I, Vuleta G, Savić S.
Vojnosanit Pregl. 2016 Nov;73(11):991-1002. doi: 10.2298/VSP150116122F.
A systematic review and meta-analysis on the safety of newly adjuvanted vaccines among children.
Stassijns J, Bollaerts K, Baay M, Verstraeten T.
Vaccine. 2016 Feb 3;34(6):714-22. doi: 10.1016/j.vaccine.2015.12.024. Epub 2015 Dec 28. Review.
Safety and efficacy of a cytomegalovirus glycoprotein B (gB) vaccine in adolescent girls: A randomized clinical trial.
Bernstein DI, Munoz FM, Callahan ST, Rupp R, Wootton SH, Edwards KM, Turley CB, Stanberry LR, Patel SM, Mcneal MM, Pichon S, Amegashie C, Bellamy AR.
Vaccine. 2016 Jan 12;34(3):313-9. doi: 10.1016/j.vaccine.2015.11.056. Epub 2015 Dec 2.
Assessment of Prime-boost Vaccination Using an AS03B-adjuvanted Influenza A (H5N1) Vaccine: A Randomized Trial in Children of Three to Less Than Eighteen Years of Age.
Izurieta P, Uy-Aragon MJ, Dramé M, Vaughn DW.
Pediatr Infect Dis J. 2016 Feb;35(2):e35-47. doi: 10.1097/INF.0000000000000968.
Randomized Controlled Trial of Adjuvanted Versus Nonadjuvanted Influenza Vaccine in Kidney Transplant Recipients.
Kumar D, Campbell P, Hoschler K, Hidalgo L, Al-Dabbagh M, Wilson L, Humar A.
Transplantation. 2016 Mar;100(3):662-9. doi: 10.1097/TP.0000000000000861.
Perinatal survival and health after maternal influenza A(H1N1)pdm09 vaccination: A cohort study of pregnancies stratified by trimester of vaccination.
Baum U, Leino T, Gissler M, Kilpi T, Jokinen J.
Vaccine. 2015 Sep 11;33(38):4850-7. doi: 10.1016/j.vaccine.2015.07.061. Epub 2015 Aug 1.
Incidence of narcolepsy before and after MF59-adjuvanted influenza A(H1N1)pdm09 vaccination in South Korean soldiers.
Kim WJ, Lee SD, Lee E, Namkoong K, Choe KW, Song JY, Cheong HJ, Jeong HW, Heo JY.
Vaccine. 2015 Sep 11;33(38):4868-72. doi: 10.1016/j.vaccine.2015.07.055. Epub 2015 Aug 1.
Paresthesia and sensory disturbances associated with 2009 pandemic vaccine receipt: Clinical features and risk factors.
De Serres G, Rouleau I, Skowronski DM, Ouakki M, Lacroix K, Bédard F, Toth E, Landry M, Dupré N.
Vaccine. 2015 Aug 26;33(36):4464-71. doi: 10.1016/j.vaccine.2015.07.028. Epub 2015 Jul 22.
Safety and persistence of the humoral and cellular immune responses induced by 2 doses of an AS03-adjuvanted A(H1N1)pdm09 pandemic influenza vaccine administered to infants, children and adolescents: Two open, uncontrolled studies.
Garcia-Sicilia J, Arístegui J, Omeñaca F, Carmona A, Tejedor JC, Merino JM, García-Corbeira P, Walravens K, Bambure V, Moris P, Caplanusi A, Gillard P, Dieussaert I.
Hum Vaccin Immunother. 2015;11(10):2359-69. doi: 10.1080/21645515.2015.1063754.
Safety and effectiveness of MF-59 adjuvanted influenza vaccines in children and adults.
Black S.
Vaccine. 2015 Jun 8;33 Suppl 2:B3-5. doi: 10.1016/j.vaccine.2014.11.062. Review.
Immunogenicity and safety of concomitant MF59-adjuvanted influenza vaccine and 23-valent pneumococcal polysaccharide vaccine administration in older adults.
Song JY, Cheong HJ, Tsai TF, Chang HA, Choi MJ, Jeon JH, Kang SH, Jeong EJ, Noh JY, Kim WJ.
Vaccine. 2015 Aug 26;33(36):4647-52. doi: 10.1016/j.vaccine.2015.05.003. Epub 2015 May 14.
A/H1N1 pandemic influenza vaccination: A retrospective evaluation of adverse maternal, fetal and neonatal outcomes in a cohort of pregnant women in Italy.
Fabiani M, Bella A, Rota MC, Clagnan E, Gallo T, D'Amato M, Pezzotti P, Ferrara L, Demicheli V, Martinelli D, Prato R, Rizzo C.
Vaccine. 2015 May 5;33(19):2240-2247. doi: 10.1016/j.vaccine.2015.03.041. Epub 2015 Mar 26.
Immunogenicity and Safety of an EB66 Cell-Culture-Derived Influenza A/Indonesia/5/2005(H5N1) AS03-Adjuvanted Vaccine: A Phase 1 Randomized Trial.
Schuind A, Segall N, Drame M, Innis BL.
J Infect Dis. 2015 Aug 15;212(4):531-41. doi: 10.1093/infdis/jiv091. Epub 2015 Feb 25.
A first-generation physiologically based pharmacokinetic (PBPK) model of alpha-tocopherol in human influenza vaccine adjuvant.
Tegenge MA, Mitkus RJ.
Regul Toxicol Pharmacol. 2015 Apr;71(3):353-64. doi: 10.1016/j.yrtph.2015.02.005. Epub 2015 Feb 12.
Immunogenicity and safety of cell-derived MF59®-adjuvanted A/H1N1 influenza vaccine for children.
Knuf M, Leroux-Roels G, Rümke H, Rivera L, Pedotti P, Arora AK, Lattanzi M, Kieninger D, Cioppa GD.
Hum Vaccin Immunother. 2015;11(2):358-76. doi: 10.4161/21645515.2014.987014.
Filters: Manage Filters